Thermogenic effect of bronchodilators in patients with chronic obstructive pulmonary disease

Burdet, Luc; de Muralt, Benoît; Schutz, Yves; Fitting, Jean-William
February 1997
Thorax;Feb1997, Vol. 52 Issue 2, p130
Academic Journal
No abstract available.


Related Articles

  • Long-acting bronchodilators raise CV risk in COPD.  // Reactions Weekly;5/25/2013, Issue 1454, p3 

    An abstract of the case study regarding the risk of bronchodilators in elderly patients with chronic obstructive pulmonary disease (COPD) is presented.

  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Hawkins, Nathaniel M.; Wang, Duolao; Petrie, Mark C.; Pfeffer, Marc A.; Swedberg, Karl; Granger, Christopher B.; Yusuf, Salim; Solomon, Scott D.; Östergren, Jan; Michelson, Eric L.; Pocock, Stuart J.; Maggioni, Aldo P.; McMurray, John J. V. // European Journal of Heart Failure;Jun2010, Vol. 12 Issue 6, p557 

    Aims: Heart failure (HF) and chronic obstructive pulmonary disease are common partners. Bronchodilators are associated with adverse cardiovascular outcomes in patients with pulmonary disease. The outcome of patients with HF prescribed bronchodilators is poorly defined.

  • An Update on Tiotropium for Chronic Obstructive Pulmonary Disease. Gupta, Rahul // Internal Medicine Alert;11/15/2008, Vol. 30 Issue 21, p163 

    The article presents a commentary to a study that determines the efficacy of adding tiotropium in bronchodilation in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

  • Considerations on the Bronchodilator Therapy in Elderly Patients with Obstructive Bronchial Syndrome. BERBECARU-IOVAN, S.; POPESCU, FLORICA; BERBECARU-IOVAN, ANCA // Current Health Sciences Journal;Oct-Dec2013, Vol. 39 Issue 4, p197 

    Aging process is related to important anatomical, physiological and psychosocial changes with a significant impact on the management of obstructive respiratory diseases (asthma and chronic obstructive pulmonary disease - COPD). Age-related changes are responsible for different efficiency of...

  • New metered-dose inhaler for bronchospasm associated with COPD.  // Modern Medicine;Jan97, Vol. 65 Issue 1, p48 

    Reports on the US Food and Drug Administration's (FDA) approval of a combination of the anticholinergic bronchodilator ipratropium bromide and the beta2-adrenergic bronchodilator albuterol sulfate for patients with chronic obstructive pulmonary disease.

  • New Product Focus.  // South African Pharmaceutical Journal;2014, Vol. 81 Issue 7, p26 

    The article focuses on the Onbrez Breezhaler® capsules or indacaterol which is a maintenance bronchodilator treatment for airflow obstruction in chronic obstructive pulmonary disease (COPD) patients. Topics discussed include mode of action, dosage, and use of Onbrez Breezhaler® capsule...

  • International COPD Coalition Column: pulmonary rehabilitation-reaching out to our international community. Garvey, Chris; Spruit, Martijn A.; Hill, Kylie; Pitta, Fabio; Shioya, Takanobu // Journal of Thoracic Disease;Jun2013, Vol. 5 Issue 3, p343 

    The article presents information on pulmonary rehabilitation (PR). PR is described as an effective intervention for people with chronic obstructive pulmonary disease (COPD). The benefits of PR for patients with COPD include, improvement in exercise capacity, enhancement in the effects of long...

  • Efficacy of Inhaled Fluticasone Plus Salmeterol in COPD. Miller, Karl E. // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2239 

    Deals with the findings of a study on the efficacy of fluticasone propionate and salmeterol in patients with chronic obstructive pulmonary disease (COPD). Use of bronchodilators as first-line therapy treatment for COPD; Effect of inhaled corticosteroids in patients with COPD; Effectiveness of...

  • Bronchodilators in COPD and Arrhythmias. Kuritzky, Louis // Internal Medicine Alert;9/15/2012, Vol. 34 Issue 17, p135 

    The article informs about a study based on the use of bronchodilators in chronic obstructive pulmonary disease (COPD) and arrhythmias.

  • Once-daily bronchodilator treatment for COPD.  // British Journal of Hospital Medicine (17508460);Nov2014, Vol. 75 Issue 11, p609 

    The article reports on the launch of Incruse Ellipta's once-daily bronchodilator for the management of symptoms of chronic obstructive pulmonary disease (COPD).


Read the Article


Sign out of this library

Other Topics